

## 9. Literaturverzeichnis

**Ahmad S, Safa AR, Glazer RI (1994):**

Modulation of P-glycoprotein by protein kinase C alpha in a baculovirus expression system. Biochemistry, 33: 10313-10318.

**Ahmed MU, Thorpe SR, Baynes JW (1986):**

Identification of N-carboxymethyllysine as a degradation product of Fructoselysine in glycated Protein. Journal of Biological Chemistry, 261: 4889-4894.

**Ames JM, Wyne A, Hofmann A, Plos S, Gibson GR (1999):**

The effect of a model melanoidin mixture on faecal bacterial population in vitro. British Journal of Nutrition, 82: 489-495.

**Anet EFLJ (1960):**

3-Deoxyhexosones. Journal of the American Chemical Society, 82: 1502-1509.

**Angrick M; Rewicki D (1980):**

Die Maillard-Reaktion. Chemie in unserer Zeit, 5: 149-157.

**Anuchapreeda S, Leechanachai P, Smith MM (2002):**

Modulation of P-glycoprotein expression and function of Curcumin in multidrug-resistant human KB cells. Biochemical Pharmacology, 64: 573-582.

**Archer SY, Meng S, Shei A, Hodin RA (1998):**

p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proceedings of the National Academy of Sciences, USA, 95: 6791-6796.

**Arima H, Yunomae K, Morikawa T, Hirayama F, Uekama K (2004):**

Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharmaceutical Research, 21 (4): 626-634.

**Baker EK, Johnstone RW, Zalberg JR, El- Osta A (2005):**

Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene, 24: 8061-8075.

**Batrakova EV, Han HY, Alakhov VY, Miller HW, Kabanov AV (1998):**

Effects of pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharmaceutical Research, 15 (6): 850-855.

**Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller HW, Kabanov AV (2003):**

Mechanism of Pluronic effect on P-glycoprotein efflux system in Blood-Brain Barrier: Contributions of energy depletion and membrane fluidization. Pharmacology and Experimental Therapeutics, 299 (2): 483-493.

**Beck J, Ledl F, Severin T (1988):**

Formation of 1-deoxy-D-erythro-2,3-hexodiulose from Amadori compounds. Carbohydrate Research, 177: 240-243.

**Behrens I, Kissel T (2003):**

Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers? European Journal of Pharmaceutical Sciences, 19: 433-442.

**Berggren AM, Björck IME, Nyman EMGL & Eggum BO (1993):**

Short-chain fatty acid content and pH in caecum of rats given various sources of carbohydrates. Journal of the Science and Food Agriculture, 63: 397-406.

**Bergmann EN (1990):**

Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. Physiological reviews, 70 (2): 567-590.

**Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L Sydow-Backmann (1998):**

Identification of a human nuclear receptor defines a new signalling pathway for CYP3A induction. Proceedings of the National Academy of Sciences, USA, 95 (21): 12208-12213.

**Bhardwaj RK, Gläser H, Bequemont L et al (2002):**

Piperine a major constituent of black pepper inhibits human P-glycoprotein and CYP3A4. The Journal of Pharmacology and Experimental Therapeutics, 302: 645-650.

**Bingham SA, Day NE, Luben R, Ferrari P, Slimani N, Norat T, et al (2003):**

Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): An observational study. Lancet, 361: 1496-501.

**Blumberg B, Sabbagh W, Juguilon H, Bolado J, Van Meter CM, Ong ES (1998):**

SXR a novel steroid and xenobiotic-sensing nuclear receptor. Genes und Development, 12 (20): 3195-205.

**Boffa LC, Gruss RJ, Allfrey VG (1981):** Manifold effects of sodium butyrate on nuclear function. Selective and reversible inhibition of phosphorylation of histones H1 and H2A and impaired methylation of lysine and arginine residues in nuclear protein fractions. Journal of Biological Chemistry, 256: 9612-9621.

**Boffa LC, Mariani MR, Parker MI (1994):** Selective hypermethylation of transcribed nucleosomal DNA by sodium butyrate. Experimental Cell Research, 211: 420-423.

**Bookchin RM, Gallop PM (1968):** Structure of haemoglobin AIc: Nature of the N-terminal beta chain blocking group. Biochemical and Biophysical Research Communications, 32: 86-93.

**Booth AA et al. (1997):**

In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. Journal of Biological Chemistry, 272: 5430-5437.

**Borelli RC, Fogliano V, Monti SM, Ames JM (2002):**

Characterisation of melanoidins from a glucose-glycine model system. European Food Research and Technology, 215: 210-215.

**Borelli RC, Fogliano V (2005):**

Bread crust melanoidins as potential prebiotic ingredients. *Molecular Nutrition and Food Research*, 49: 673-678.

**Borelli RC, Visconti A, Mennella C, Anese M, Fogliano V (2002):**

Chemical characterisation and antioxidant properties of coffee melanoidins. *Journal of Agricultural and Food Chemistry*, 50: 6527-6533.

**Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L (2000):** Atorvastatin coadministration may increase Digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. *Journal of Clinical Pharmacology*, 40 (1): 91-98.

**Brands CMJ, Alink GM, van Boekel MAJS, Jongen WMF (2000):**

Mutagenicity of heated sugar-casein systems: Effect of the Maillard reaction. *Journal of Agricultural and Food Chemistry*, 48: 2271-2275.

**Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT (1993):**

Interleukin-2 and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. *Immunology*, 78: 127-131.

**Breves G, Schulze E, Sallmann HP, Gädeken D (1993):**

The application of <sup>13</sup>C-labelled short chain fatty acids to measure acetate and propionate production rates in the large intestines. Studies in a pig model. *American Journal of Gastroenterology*, 31: 179-182.

**Brownlee M, Cerami A, Vlassara H (1988):**

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. *The New England Journal of Medicine*, 318 (20): 1315-21.

**Brownlee M (1995):** The pathological implications of protein glycation. *Clinical and Investigative Medicine*, 18 (4): 275-81.

**Bugaut M (1987):**

Occurrence, absorption and metabolism of short chain Fatty acids in the digestive tract of mammals. *Comparative Biochemistry and Physiology*, 86B: 439-472.

**Bunn HF, Haney DN, Gabbay KH, Gallop PM (1975):**

Further identification of the nature and linkage of the carbohydrate in haemoglobin A1c. *Biochemical and Biophysical Research Communications*, 67: 103-109.

**Buss N, Snell P, Bock J, Hsu A, Jorga K (2001):**

Saquinavir and Ritonavir pharmacokinetics following combined Ritonavir and Saquinavir administration. *British Journal of Clinical Pharmacology*, 52: 255-264.

**Chai F, Evdokiou A, Young GP, Zalewski PD (2000):**

Involvement of p21 (WAF1/ Cip1) and its cleavage by DEVD-caspase during apoptosis of colorectal cancer cells induced by butyrate. *Journal of Carcinogenesis*, 21: 7-14.

**Chandra R, Bharagava RN, Rai V (2008):**

Melanoidins as major colorant in sugarcane molasses based distillery effluent and its degradation. *Bioresource Technology*, 99(13):4648-4660.

**Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM (1999):**

Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. *Cell*, 98 (5): 675-86.

**Cherrington CA, Hinton M, Pearson GR, Chopra I (1991):**

Short-chain organic acids at pH 5.0 kill Escherichia coli and Salmonella spp without causing membrane perturbation. *The Journal of Bacteriology*, 70: 161-165.

**Choi C-H, Kang G, Min Y-D (2003):**

Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. *Planta Medica*, 69:235-40.

**Christians U (2004): Transport Proteins and Intestinal Metabolism: P-Glycoprotein and Cytochrome P4503A. Therapeutic Drug Monitoring**, 26: 104-106.**Collet A, et al (2004):**

Rapid induction of P-glycoprotein expression by high permeability compounds in colonic cells in vitro: A possible source of transporter mediated drug interactions?  
*Biochemical Pharmacology*, 68: 783-790.

**Cook SI, Sellin JH (1998):**

Short-chain fatty acids in health and disease.  
*Alimentary Pharmacology and Therapeutics*, 12: 499-507.

**Cuff MA, Shirazi- Beechey SP (2004):**

The importance of butyrate transport to the regulation of gene expression in the colonic epithelium. *Biochemical Society Transaction*, 32: 1100-1102.

**Cummings JH, Pomare EW, Branch WJ, Naylor CPE, Macfarlane GT (1987):**

Short-chain fatty acids in human large intestine, portal, hepatic and venous blood.  
*Journal of Gastroenterology and Hepatology*, 28: 1221-1227.

**Cummings JH (1981):**

Short-chain fatty acids in the human colon.  
*Journal of Gastroenterology and Hepatology*, 22: 763-79.

**Cummins CL, Jacobsen W, Benet LZ (2002):**

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.  
*Pharmacology and Experimental Therapeutics*, 300 (3): 1036-1045.

**D'Souza VM, Shertzer HG, Menon AG, Pauletti GM (2003):**

High Glucose concentration in isotonic media alters Caco-2 cell permeability.  
*Pharmaceutical Sciences*, 5 (3) Article 24.

**Daglia M, Papetti A, Gregotti C, Berte F, Gazzani G (2000):**

In vitro antioxidant and ex vivo protective activities of green and roasted coffee.  
*Journal of Agricultural and Food Chemistry*, 48: 1449-1454.

**Daly K, Shirazi-Beechey SP (2006):**

Microarray analysis of butyrate regulated genes in colonic epithelial cells.  
DNA and Cell Biology, 25 (1): 49-62.

**Delgado-Andrade C, Morales FJ (2005):**

Unravelling the contribution of melanoidins to the antioxidant activity of coffee brews.  
Journal of Agricultural and Food Chemistry, 53: 1403-1407.

**Dell'Aquila C, Ames JM, Gibson GR, Wynne AG (2003):**

Fermentation of heated gluten systems by gut microflora. European Food Research and Technology, 217: 382-386.

**Ding QM, Ko TC, Evers BM (1998):**

Caco-2 intestinal cell differentiation is associated with G1 arrest and suppression of CDK2 and CDK4. American Journal of Physiology-Cell Physiology, 275: 1193-1200.

**Doige CA, Yu X, Sharom FJ (1993):**

The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids, 1146: 65-72.

**Dresser GK, Schwarz UI, Wilkinson GR, Kim RB (2003):**

Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clinical Pharmacology and Therapeutics, 73(1): 41-50.

**Drozdik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003):**

Polymorphism in the P-glycoprotein drug transporter MDR1 gene: A possible link between environmental and genetic factors in Parkinson's disease. Pharmacogenetics, 13: 259-263.

**Durr D, Steiger B, Kullak-Ublick GA, et al (2000):**

St John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clinical Pharmacology and Therapeutics, 68: 598-604.

**Ecker G, Huber M, Schmid D, Chiba P (1999):** The importance of a nitrogen atom in modulators of multidrug resistance. Molecular Pharmacology, 56: 791-796.**Eichelbaum M, Fromm MF, Schwab M (2004):**

Clinical Aspects f the MDR1 (ABCB1) gene polymorphism.  
Therapeutic Drug Monitoring, 26 (2): 180-185.

**Emenaker NJ, Calaf GM, Cox D, Basson MD, Qureshi N (2001):**

Short-chain fatty acids inhibit invasive human colon cancer by modulating uPA, TIMP-1, TIMP-2, mutant p53, Bcl-2, Bax, p21 and PCNA protein expression in an in vitro cell culture model. Journal of Nutrition, 131: 3041-3046.

**Engelhardt von W (1995):**

Absorption of short-chain fatty acids from the large intestine. Physiological and clinical aspects of short-chain fatty acids. Cambridge University Press, 149-170.

**Eytan GD, Regev R, Assaraf YG (1996):**

Functional reconstitution of P-glycoprotein reveals an apparent near stoichiometric drug transport to ATP hydrolysis. Journal of Biological Chemistry, 271: 3172-3178.

**Fais S, Capobianchi MR, Pallone F, Di Marco P, Boirivant M, Dianzani F, Torsoli A (1991):** Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn's disease. Kinetics of in vitro response to interferon gamma inducers. Journal of Gastroenterology and Hepatology, 32: 403-407.

**Fais S, Capobianchi MR, Silvestri M, Mercuri F, Pallone F, Dianzani F:** Interferon expression in Crohn's disease patients: Increased interferon-gamma and -alpha mRNA in the intestinal lamina propria mononuclear cells. Journal of Interferon Research, 14 (5): 235-238.

**Faist V, Lindenmeier M, Geisler C, Erbersdobler HF, Hofmann T (2002):** Influence of Molecular Weight Fractions isolated from roasted Malt on the Enzyme Activities of NADPH-Cytochrome *c*-reductase and Glutathione-S-transferase in Caco-2 cells. Journal of Agricultural and Food Chemistry, 50: 602-606.

**Finot PA, Magneat E (1981):** Metabolic transit of early and advanced Maillard products. Progression Food Nutrition Science, 5: 193-207.

**Fitch MD, Fleming SE (1999):** Metabolism of short-chain fatty acids by rat colonic mucosa in vivo. American Journal of Physiology, 277: 31-40.

**Gaschott T, Stein J (2003):** Short-chain fatty acids and colon cancer cells: The vitamin D receptor butyrate connection. Recent Results Cancer Research, 164: 247-257.

**Gaschott T, Werz O, Steinmeyer A, Steinhilber D, Stein J (2001):** Butyrate-induced differentiation of Caco-2 cells is mediated by Vitamin D receptor. Biochemical and Biophysical Research Communications, 288: 690-696.

**Gibson GR, Roberfroid MB (1995):** Dietary modulation of the human colonic microbiota: Introducing the concept of prebiotics. Journal of Nutrition, 125: 1401-1412.

**Gonzalez CA (2006):** The European Prospective Investigation into Cancer and Nutrition (EPIC). The Lancet, 9 (1A):124-126.

**Gottesman M.M (2002):** Mechanisms of cancer drug resistance. Annual Review. Med. 53: 615-627.

**Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, Von Richter O, Zundler J, Kroemer HK (1999):** The role of intestinal P-glycoprotein in the interaction of Digoxin and Rifampin. The Journal of Clinical Investigation, 104 (2): 147-153.

**Grossklaus R (1983):** Energy gap?. Nutrition Research, 3: 595-604.

**Grubben MJ, van den Braak CC, Essenberg M et al (2001):**

Effect of resistant starch on potential biomarkers for colonic cancer risk in patients with colonic adenomas: A controlled trial. *Digestive diseases and science*, 46: 750-756.

**Grunstein M (1997):**

Histone acetylation in chromatin structure and transcription. *Nature*, 389: 349-352.

**Hague A, Elder DJ, Hicks DJ, Paraskeva C (1995):**

Apoptosis in colorectal tumour cells: induction by the short-chain fatty acids butyrate, propionate, acetate and by the bile salt deoxycholate. *International Journal of Cancer*, 60: 400-406.

**Hague A, Paraskeva C (1995):**

The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines, *European Journal of Cancer Prevention*, 4: 359-364.

**Hansen MB, Nielson SE, Berg K (1989):**

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *Journal of Immunological Methods*, 119 (2): 203-210.

**Hayashi T, Namiki M (1980):**

Formation of two-carbon sugar fragments at an early stage of the browning reaction of sugar and amine. *Agricultural and Biological Chemistry*, 44: 2575-2580.

**Higgins CF, Gottesmann MM (1992):**

Is the multidrug transporter a flipase? *Trends in Biochemical Sciences*, 17: 18-21.

**Higgins CF, Linton KJ (2004):**

The ATP switch model for ABC transporters. *Nature Structural and Molecular Biology*, 11 (10): 918-926.

**Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA (2002):**

The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. *Journal of Nutrition*, 132: 1012-1017.

**Hodge JE (1953):**

Chemistry of browning reactions in model systems. *Journal of Agricultural and Food Chemistry*, 1: 928-943.

**Hoffmann T, Ames J, Krome K, Faist V (2001):**

Determination of the molecular weight distribution of non-enzymatic browning products formed by roasting of glucose and glycine and studies on their effects on NADPH-cytochrome c-reductase and glutathione-S-transferase in Caco-2 cells. *Nahrung/Food*, 45 (3): 189-194.

**Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, Cacscorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000):**

Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. *Proceedings of the National Academy of Sciences, USA*, 97: 3473-3478.

**Hold GL, Schwierz A, Aminov RI, et al (2003):**

Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human faeces. *Applied and Environmental Microbiology*, 69: 4320-4324.

**Homma S & Fujimaki M (1981):**

Growth response of rats fed a diet containing nondialyzable melanoidin.

Maillard Reactions in Food, 209-216.

**Hosoya KI, Kim KJ, Lee VH (1996):**

Age-dependent expression of P-glycoprotein in Caco-2 cell monolayers.

*Pharmaceutical Research*, 13 (6): 885-890.

**Jodoin J, Demeule M, Beliveau R (2002):**

Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols.

*Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids*, 1542 (1-3): 149-159.

**Joseph J, Mudduluru G, Antony S, Vashistha S, Ajitkumar P, Somasundaram K (2004):**

Expression profiling of sodium butyrate-treated cells: identification of regulation of genes related to cytokine signalling and cancer metastasis by Na-Butyrate.

*Oncogene*, 23: 6304-6315.

**Juliano RL, Ling (1976):**

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

*Biochimica et Biophysica Acta – Molecular and Cell Biology of Lipids*, 455 (1): 152-162.

**Kawakishi S, Tsunehiro J, Uchida K (1991):**

Autoxidative degradation of Amadori compounds in the presence of copper ion.

*Carbohydrate Research*, 211: 167-171.

**Kim S-W, Kwon HY, Chi D-W et al (2003):**

Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg (3).

*Biochemical Pharmacology*, 65: 75-82.

**Kipp H and Arias IM (2002):**

Trafficking of canalicular ABC transporter in hepatocytes. *Annual Review of Physiology*, 64: 595-608.

**Kitts DD, Wu CH, Powrie WD (1993):**

Effect of glucose- lysine Maillard reaction product fractions on tissue xenobiotic enzyme systems. *Journal of Agricultural and Food Chemistry*, 41: 2359-2363.

**Klinder A, Gietl E, Hughes R, Jonkers N, Karlsson P, McGlyn H, Pistoli S, Tuohy KM,**

**Rafter J, et al (2004):** Gut fermentation products of inulin-derived prebiotics beneficially modulate markers of tumour progression in human colon tumour cells.

*International Journal of Cancer Prevention*, 1: 19-32.

**Koenig R et al (1976):**

Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus

*The New England Journal of Medicine*, 295: 417-420.

**Krishna G, Chen K, Lin C, Nomeir AA (2001):**

Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model Caco-2. International Journal of Pharmacy, 222 (1): 77-89.

**Kume S., et al (1995):**

Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. American Journal of Pathology, 147 (3): 654-67.

**Kunzelmann K, Schreiber R, König J, Mall M (2002):**

Ion transport induced by proteinase-activated receptors (PAR2) in colon and airways. Cell Biochemistry and Biophysics, 36 (2-3): 209-214.

**Lambert DW, Wood IS, Ellis A, Shirazi-Beechey SP (2002):**

Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy British Journal of Cancer, 70: 733-736.

**Ledl F, Schleicher E (1990):**

Die Maillard-Reaktion in Lebensmitteln und im menschlichen Körper. Angewandte Chemie, 102: 597-626.

**Lee G, Bendayan R (2004):**

Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharmaceutical Research, 21: 1313-1330.

**Lee IE, van Chuyen N, Hayase F & Kato F (1992):**

Absorption and distribution of [14C]melanoidins in rats and the desmutagenicity of absorbed melanoidins against trp-P-1. Bioscience, Biotechnology and Biochemistry, 56: 21-23.

**Lehmann JM, Mc Kee DD, Watson MA, Willson TM, Moore JT, Kliewer SA (1998):**

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP 3A4 gene expression and cause drug interactions. The Journal of Clinical Investigation, 102 (5): 1016-23.

**Limtrakul P, Anuchapreeda S, Buddhasukh D (2004):**

Modulation of human multidrug-resistance MDR-1 gene by natural curcuminoids. BMC Cancer, 4-13.

**Livesey G (1990):**

Energy values of unavailable carbohydrate and diets: an inquiry and analysis. American Journal of Clinical Nutrition, 51: 617-637.

**Lo YL (2003):**

Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines. Journal of Controlled Release, 90 (1): 37-48.

**Loo TW, Clarke DM (1997):**

Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate. Journal of Biological Chemistry, 272: 31945-31948.

**Loo TW, Clarke DM (2000):**

Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteine-scanning mutagenesis and reaction with dibromobimane. Journal of Biological Chemistry, 275: 39272-39278.

**Lupton JR (2004):**

Microbial degradation products influence colon cancer risk: the butyrate controversy. Journal of Nutrition, 134: 479-82.

**Macfarlane GT, Macfarlane S (1997):**

Human colonic microbiota: Ecology, physiology and metabolic potential of intestinal bacteria. Scandinavian Journal of Gastroenterology, Supplement, 222:3-9.

**Macfarlane S, Macfarlane GT, Cummings JH (2006):**

Prebiotics in the gastrointestinal tract.

Alimentary Pharmacology and Therapeutics, 24: 701-714.

**Maillard MN, Billaud C, Chow YN, Ordonaud C, Nicolas J (2007):**

Free radical scavenging, inhibition of polyphenoloxidase activity and copper chelating properties of model Maillard systems.

Swiss Society of Food Science and Technology, 40: 1434-1444.

**Marko D, Habermeyer M, Kemeny M, Weyand U, Niederberger E, Frank O, Hofmann T (2003):**

Maillard reaction products modulating the growth of he human tumour cells in vitro.

Chemical Research in Toxicology, 16: 48-55.

**Marko D, Kemeny M, Bernady E, Habermeyer M, Weyand U, Meiers S, Frank O, Hofmann T (2002):**

Studies on the inhibition of tumour cell growth and microtubule assembly by 3-hydroxyl-4-((E)-(2-furyl) methylidene) methyl-3-cyclopentene-1,2-dione, an intensively coloured Maillard reaction product. Food and Chemical Toxicology, 40: 9-18.

**McMillan L, Butcher SK, Pongracz J, Lord JM (2003):**

Opposing effects of butyrate and bile acids on apoptosis of human colon adenoma cells: Differential activation of PKC and MAP kinases. British Journal of Cancer, 88: 748-753.

**Mei Y, Qian F, Wei D et al (2004):**

Reversal of cancer multidrug resistance by green tea polyphenols.

Journal of Pharmacy and Pharmacology, 56: 1307-1314.

**Metz TO et al. (2003):**

Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: Evidence on the role of lipids in chemical modification of protein and development of diabetic complications.

Journal of Biological Chemistry, 278: 42012-42019.

**Modok S, Heyward C, Callaghan R (2004):**

P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterolrich environment. Journal of Lipid Research, 45: 1910-1918.

**Monti SM, Ritieni A, Graziani G, Randazzo G, Mannina L, Segra AL, & Fogliano V (1999):**

LC/MS analysis and antioxidative efficiency of Maillard reaction products from a lactose-lysine model system. *Journal of Agricultural and Food Chemistry*, 47: 1506-1513.

**Munch G, Thome J, Foley P, Schinzel R, Riederer P (1997):**

Advanced glycation endproducts in ageing and Alzheimer's disease. *Brain Research Reviews*, 23: 134-143.

**Nair BM, Oste R, Asp NG & Pernemalm PA (1981):**

Absorption and distribution of a C14-glucose lysine reaction mixture in the rat. *Maillard Reactions in Food*, 217-222.

**Nakanishi K, Nadai T, Masada M, Miyajima K (1992):**

Effect of cyclodextrins on biological membrane. II. Mechanism of enhancement on the intestinal absorption of non-absorbable drug by cyclodextrins. *Chemical and Pharmaceutical Bulletin*, 40 (5): 1252-1256.

**Nawroth PP et al (1999):**

Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus. *Medizinische Klinik*, 94 (1): 29-38.

**Nerukar MM, Burton PS, Borchardt RT (1996):**

The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. *Pharmaceutical Research*, 13 (4): 528-534.

**Neuhoff S, Ungell AL, Zamora I, Artursson P (2003):**

pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: Implications for drug-drug interactions. *Pharmaceutical Research*, 20 (8): 1141-1148.

**Newmark HL, Lupton JR (1990):**

Determinants and consequences of colonic luminal pH: Implications for colon cancer. *Nutrition and Cancer*, 14: 161-173.

**Panchagnula R, Bansal T, Varma MV, Kaul CL (2005):**

Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux. *Pharmazie*, 60 (12): 922-927.

**Perloff MD, von Moltke LL, Stormer E et al (2001):**

Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extend exposure *British Journal of Pharmacology*, 134: 1601-1608.

**Perloff MD, Von Moltke LL, Störmer E, Shader RI, Greenblatt DJ (2001):**

Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. *British Journal of Pharmacology*, 134: 1601-1608.

**Pfrunder A, Gutmann H, Beglinger C, Drewe J (2003):** Gene expression of CYP3A4, ABC-transporters and hPXR in three different human colon carcinoma cell lines *Journal of Pharmacy and Pharmacology*, 55 (1): 59-66.

**Pfrunder A, Gutmann H, Beglinger C, Drewe J (2003):**

Gene expression of CYP3A4, ABC-transporters (MDR1 and MRP1-MRP5) and hPXR in three different human colon carcinoma cell lines.

The Journal of Pharmacy and Pharmacology, 55 (1): 59-66.

**Pirart J (1978):**

Diabetes mellitus and its degenerative complications: prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care, 188: 252-263.

**Powrie WD, Wu CH, Molund VP (1986):**

Browning reaction systems as sources of mutagens and antimutagens. Environmental Health Perspectives, 67: 47-54.

**Powrie WD, Wu CH, Molund VP (1986):**

Browning reaction systems as sources of mutagens and antimutagens. Environmental Health Perspectives, 67: 47-54.

**Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH (2004):**

Differential Multidrug Resistance-associated Protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells.

The Journal of Pharmacology and Experimental Therapeutics Fast Forward, 311: 476-484.

**Prohaszka L, Jayarao BM, Fabian A, Kovacs S (1990):**

The role of intestinal volatile fatty acids in the Salmonella shedding of pigs. Zentralblatt für Veterinärmedizin, B, 37: 570-574.

**Reddy VP, Beyaz A (2006):**

Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discovery Today, 11 (13/14): 646-653.

**Rege BD, Kao JPY, Polli JE (2002):**

Effects of non-ionic surfactants on membrane transporters in Caco-2 monolayers. European Journal of Pharmaceutical Sciences, 16 (4): 237-246.

**Roediger WEW (1980):**

Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut, 21: 793-798.

**Roediger WEW (1982):**

Utilization of nutrients by isolated epithelial cells of the rat colon. Gastroenterology, 83: 424-429.

**Romsicki Y, Sharom FJ (1999):**

The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry, 38: 6887-6896.

**Rosenberg MF, Callaghan R, Ford RC, Higgins CF (1997):**

Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis.

Journal of Biology and Chemistry, 272: 10685-10694.

**Rufian-Henares JA, Morales FJ (2007):**

Functional properties of melanoidins: In vitro antioxidant, antimicrobial and antihypertensive activities. *Food Research International*, 40: 995-1002.

**Sachs CW, Chambers TC, Fine RL (1999):**

Differential phosphorylation of sites in the linker region of P-glycoprotein by protein kinase C isoforms  $\alpha$ ,  $\beta$  I,  $\beta$  II,  $\gamma$ ,  $\delta$ ,  $\epsilon$ ,  $\eta$  and  $\zeta$ . *Biochemical Pharmacology*, 58: 1587-1592.

**Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F (2005):**

The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. *Cell Biology and Toxicology*, 21: 1-26.

**Sauna ZE, Ambudkar SV (2001):**

Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. *Journal of Biological Chemistry*, 276: 11653-11661.

**Scheppach W, Weiler F (2004):**

The butyrate story: Old wine in new bottles?  
*Current Opinion in Clinical Nutrition and Metabolic Care*, 7: 563-567.

**Scheppach W, Bartram HP, Richter F (1995):**

Role of short-chain fatty acids in the prevention of colorectal cancer.  
*European Journal of Cancer*, 31A: 1077-80.

**Schlachetzki F and Pardridge WM (2003):**

P-glycoprotein and caveolin-1 $\alpha$  in endothelium and astrocytes of primate brain.  
*Neuroreport*, 14: 2041-2046.

**Senior AE, Al-Shawi MK, Urbatsch IL (1995):**

The catalytic cycle of P-glycoprotein. *FEBS Letters*, 377: 285-289.

**Sharom FJ (1997b):**

The P-glycoprotein multidrug transporter: interaction with membrane lipids, and their modulation of activity *Biochemical Society Transactions*, 25: 1088-1096.

**Siavoshian S, segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottiere HM (2000):**

Butyrate and Trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: Induction of cyclin D3 and p21 expression. *Gut*, 46: 507-514.

**Singh R. et al (2001):**

Advanced glycation end-products: A review. *Diabetologia*, 44 (2): 129-46.

**Smith PK, et al (1985):**

Measurement of protein using bicinchoninic acid. *Anal. Biochemistry*, 150: 76-85.

**Solyakov A, Skog K, Jägerstad M (2002):**

Binding of mutagenic/carcinogenic heterocyclic amines to MRPs under stimulated gastrointestinal conditions. *Melanoidins in Food and Health*, EC Directorate for Research, 3: 195-197.

**Somoza V (2005):**

Five years of research on health risks and benefits of Maillard reaction products: An update. Molecular Nutrition and Food Research, 49: 663-672.

**Spahn Langguth H, Langguth P (2001):**

Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate Talinolol. European Journal of Pharmaceutical Sciences, 12: 361-367.

**Stadler K et al. (2005):**

Beneficial effects of aminoguanidine on the cardiovascular systems of diabetic rats. Diabetis Metabolism Research Reviews, 21: 189-196.

**Stein J, Zores M, Schröder O (2000):**

Short-chain fatty acid (SCFA) uptake into Caco-2 cells by a pH-dependent and carrier mediated transport mechanism European Journal of clinical Nutrition, 39: 121-125.

**Stern R, Vidali G, Allfrey VG (1981):**

Studies of acetylation and deacetylation in high mobility group proteins: Identification of the sites of acetylation in high mobility group proteins 14 and 17. Journal of Biological Chemistry, 256: 8892-8895.

**Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, Amidon GL (2002):**

Comparison of human duodenum and Caco-2 gene expression Profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharmaceutical Research, 19 (10): 1400-1416.

**Suzuki T, Yoshida S, Hara H (2008):**

Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. The British Journal of Nutrition, 100 (2):297-305.

**Sweatman TW, Seshadri R, Israel M (1990):**

Metabolism and elimination of Rhodamine 123 in the rat. Cancer Chemotherapy and Pharmacology, 27: 205-210.

**Swennen K, Courtin CM, Delcour JA (2006):** Non-digestible oligosaccharides with prebiotic properties. Critical Reviews in Food Science and Nutrition, 46: 459-471.**Taylor JLS, Demyttenaere JCR, Tehrani KA, Olave CA, Regniers L, Verschaeve L, Maes A, Elgorashi EE, Van Staden J, De Kimpe N (2004):**

Genotoxicity of Melanoidin Fractions derived from a standard glucose/glycin Model. Journal of Agricultural and Food Chemistry, 52: 318-323.

**Thomas MC et al. (2005):**

The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Current Drug Targets, 6: 453-474.

**Thornalley PJ (1998):**

Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell and Molecular Biology, 44 (7): 1013-23.

**Topping DL, Illmann, Clarke JM, Trimble RP, Jackson KA, Marsono Y (1993):**  
Dietary fat and fiber alter large bowel and portal venous volatile fatty acids and plasma cholesterol but not biliary steroids in pigs. *Journal of Nutrition*, 123: 133-143.

**Troutman MD, Thakker DR (2003):**

Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-Glycoprotein in cell culture models in intestinal epithelium. *Pharmaceutical Research*, 20 (8): 1210-1224.

**Troutman MD, Thakker DR (2003):**

Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells. *Pharmaceutical Research*. 20 (8): 1192-1199.

**Valls-Belles V, Torres MC, Muniz P, Boix L et al (2004):**

The protective effects of melanoidins in Adriamycin-induced oxidative stress in rat isolated hepatocytes. *Journal of the Science of Food and Agriculture*, 84: 1701-1707.

**Venter CS, Vorster HH, Cummings JH (1990):**

Effects of dietary propionate on carbohydrate and lipid metabolism in healthy volunteers. *American Journal of Gastroenterology*, 85: 549-553.

**Vogelsang S, Cascorbi I, Schröder E, Pahnke J, Krömer HK, Siegmund W, Kunert-Keil C, Walker C, Warzki RW (2002):**

Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. *Pharmacogenetics*, 12: 535-541.

**Walgren RA, Walle T (1999):**

The influence of Plasma Binding on Absorption/ Exsorption in the Caco-2 Model of Human Intestinal Absorption. *Journal of Pharmaceutical Pharmacology*, 51: 1037-1040.

**Wang RB, Kuo CL, Lien LL, Lien EJ (2003):**

Structure-activity relationship: analysis of P-glycoprotein substrates and inhibitors. *Journal of Clinical Pharmacology and Therapeutics*, 28 (3): 203-228.

**Wang S-W, Monagle J, Mc Nulty C, Putnam D, Chen H (2004):**

Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process. *Journal of Pharmaceutical Sciences*, 93 (11): 2755-2767.

**Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR (2003):**

2.1 crystal structure of human PXR in complex with the St. John's wort compound Hyperforin. *Biochemistry* 42 (6): 1430-1438.

**Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP (2001):**

The human nuclear receptor PXR: structural determinants of directed promiscuity. *Science*, 292 (5525): 2329-2333.

**Wenzel E, Tasto S, Erersdöbler HF, Faist V (2002):**

Effect of heat-treated proteins on selected parameters of the biotransformation system in the rat. *Annals of Nutrition and Metabolism*, 46: 9-16.

**Westphal G, Kroh L (1985):**

Zum Mechanismus der frühen Phase der Maillard-Reaktion. Einfluss der Struktur des Kohlenhydrates und der Aminosäure auf die Bildung des N-Glycosids.  
Die Nahrung, 29 (8): 757-764.

**Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W (2000):**

Oral bioavailability of Digoxin is enhanced by Talinolol: Evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and Therapeutics, 68 (4): 311-318.

**Wijewickreme AN, Kitts DD, Durance TD (1997):**

Reaction conditions influence the elementary composition and metal chelating affinity of nondialyzable model Maillard reaction.  
Journal of Agricultural and Food Chemistry, 45: 4577-4583.

**Williams BA, Tannock GW, Tamminga S (2001):**

Fermentation in the large intestine of single-stomached animals and its relationship to animal health. Nutrition Research Reviews, 14: 207-227.

**Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ (2006):**

Colonic health: fermentation and short-chain fatty acids.

Journal of Clinical Gastroenterology, 40: 235-243.

**Xu J, Go ML, Lim- L-Y (2003):** Modulation of Digoxin transport across Caco-2 cell monolayers by citrus fruit juices: Lime, lemon, grapefruit and pummelo.

Pharmaceutical Research, 20: 169-176.

**Yang W, Freedman LP (1999):**

20-Epi analogues of 1,25-dihydroxyvitamin D<sub>3</sub> are highly potent inducers of DRIP coactivator complex binding to the vitamin D<sub>3</sub> receptor.

Journal of Biological Chemistry, 274 (24): 16838-45.

**Yee S (1997):**

In vitro permeability across Caco-2 cells can predict in vivo absorption in man-Fact or myth.  
Pharmaceutical Research, 14 (6): 763-766.

**Yilmaz Y, Toledo R (2004):**

Antioxidant activity of water-soluble Maillard reaction products.

Food Chemistry, 93: 273-278.

**Yim HS, Kang SO, Hah YC, Chock PB, Yim MB (1995):**

Free radicals generated during the glycation reaction of amino acids by Methylglyoxal.  
Journal of Biological Chemistry, 270: 28228-28233.

**Yoshimura Y, Iijima T, Watanabe T, & Nakazawa H (1997):**

Antioxidative effect of Maillard reaction products using glucose-glycine model system.  
Journal of Agricultural and Food Chemistry, 45: 4106-4109.

**Zhang S, Morris ME (2003):**

Effects of the flavonoids Biochanin A, Morin, Phloretin and Silymarin on P-glycoprotein-mediated transport.

The Journal of Pharmacology and Experimental Therapeutics, 304: 1258-1267.

**Zhang Z, Wu JY, Hait WN, Yang JM (2004):**

Regulation of the stability of P-glycoprotein by ubiquitination.

Molecular Pharmacology, 66: 395-403.

**Zoran DL, Turner ND, Taddeo SS, Chapkin RS, Lupton JR (1997):**

Wheat ban diet reduces tumour incidence in a rat model of colon cancer independent of effects on distal luminal butyrate concentrations. Journal of Nutrition, 127: 2217-2225.